New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. $CRL

New York State Common Retirement Fund cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 15.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,008 shares of the medical research company's stock after selling 20,812 shares during the quarter. New York State Common Retirement Fund owned about 0.23% of Charles River Laboratories International worth $16,843,000 as of its most recent SEC filing.

• The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its holdings in shares of Charles River Laboratories International by 1.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company's stock valued at $871,000 after acquiring an additional 76 shares during the last quarter. Brooklyn Investment Group lifted its position in Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after purchasing an additional 86 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International by 1.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company's stock valued at $1,072,000 after purchasing an additional 86 shares during the last quarter. WESCAP Management Group Inc. grew its position in Charles River Laboratories International by 3.8% during the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company's stock worth $371,000 after purchasing an additional 89 shares during the period. Finally, State of New Jersey Common Pension Fund D raised its stake in shares of Charles River Laboratories International by 0.7% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company's stock valued at $2,553,000 after buying an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

CRL stock opened at $175.10 on Wednesday. The company has a market capitalization of $8.62 billion, a P/E ratio of -112.24, a PEG ratio of 6.22 and a beta of 1.63. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $202.72. The business has a 50 day simple moving average of $172.64 and a 200-day simple moving average of $160.81. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion for the quarter, compared to analysts' expectations of $990.43 million. During the same period in the previous year, the company posted $2.59 EPS. The company's quarterly revenue was down .5% on a year-over-year basis. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on CRL shares. Baird R W upgraded Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 6th. TD Cowen decreased their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a "buy" rating on the stock in a research report on Monday, November 10th. William Blair upgraded shares of Charles River Laboratories International from a "market perform" rating to an "outperform" rating in a report on Monday, October 6th. JPMorgan Chase & Co. increased their price objective on Charles River Laboratories International from $160.00 to $165.00 and gave the company a "neutral" rating in a report on Thursday, November 6th. Finally, Barclays upped their target price on shares of Charles River Laboratories International from $195.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $190.86.

View Our Latest Analysis on CRL

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

• Five stocks we like better than Charles River Laboratories International
• How Technical Indicators Can Help You Find Oversold Stocks
• Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
• 3 Home Improvement Stocks that Can Upgrade Your Portfolio
• Checkmate in the Cloud: ServiceNow's Shopping Spree
• Election Stocks: How Elections Affect the Stock Market
• The Contrarian Case for MSTR Amid MSCI Delisting Debacle

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here